How should I approach advance care planning (ACP) and goals of care (GOC) discussions with patients living with dementia? 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
30/100
As dementia progresses to advanced stages, the need for compassionate and person-centred care becomes paramount. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The National Dementia Care Collaborative (NDCC) aims to improve access to and successful implementation of evidence-based comprehensive dementia care. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
29/100
A Doença de Alzheimer (DA) é uma das condições neurodegenerativas mais prevalentes do Sistema Nervoso Central (SNC), caracterizada pelo acúmulo anormal de placas beta-amilóide (Aβ) e emaranhados neurofibrilares, levando à degeneração neuronal e ao comprometimento progressivo das funções cognitivas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Introducción: La enfermedad de Alzheimer (EA) representa la causa más común de demencia a nivel mundial, caracterizada por un deterioro progresivo de la memoria y otras funciones cognitivas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dürfen Medikamente mit minimaler Wirkung und im Einzelfall schweren Nebenwirkungen (auf die hier aus Platzgründen nicht weiter eingegangen wird), den PatientInnen, die sich ja auch große Hoffnungen machen, zugemutet werden? 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As of April 3, 2025, 944 HCPs (neurologists 14%, geriatricians 5%, primary care providers 25%) and 2,269 P/Cs engaged with the contents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The VHA is well-positioned to use a hybrid approach-both telehealth and in-person care-to support the provision of amyloid-targeting therapies for veterans with AD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, a progressive neurodegenerative disorder affecting memory, cognition, and behaviour, poses a major global health challenge in aging populations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent studies highlight the significance of plasma phosphorylated tau proteins, neurofilament light chain, and amyloid-beta ratios as reliable biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Bilgisayar destekli cihaz ve sistemlerin sağlık sektöründe giderek artan kullanımı, hastalıkların daha erken ve daha hızlı teşhis edilmesine olanak sağlamaktadır. Bilgisayar destekli sistem ve cihazlar özellikle nörolojik hastalıkların tanı ve görüntülemesinde kritik bir rol oynamaktadır. Merkezi sinir sistemi ve bilişsel fonksiyonların değerlendirilmesindeki gelişmeler, özellikle Alzheimer Hastalığı gibi nörodejeneratif hastalıkların erken teşhisinde önemli avantajlar sağlamaktadır. Çalışmada kullanılan veriler Kaggle platformunda açık kaynaklı olarak bulunan “Augmented Alzheimer MRI Dataset” isimli veri setinden alınmıştır. Bu veri setinde ikinci klasör kullanılmıştır. Toplamda 33.894 adet görüntü bulunmaktadır. Çalışmada Alzheimer hastalığı teşhisi analizi için derin öğrenme sınıflandırıcı model olarak Convolutional Neural Network (CNN) kullanılmıştır. Performans analizi yapılmıştır. Kullanılan CNN model accuracy değerini 0.9102 olarak vermiştir. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With increasing dementia prevalence and reliance on spousal care partners, understanding how caregiving identity evolves and how resilience is fostered across the care trajectory is crucial. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, including Alzheimer’s disease and related dementias (ADRD), is a major cause of death among older adults in the United States. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite having an increased risk of developing dementia, individuals from minority ethnic communities are largely overlooked by research and dementia services and are less likely to receive timely diagnosis and appropriate support. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individuals aged 70 and above experiencing memory loss in Cochran and Parmer Counties had a statistically significant association with cognitive impairment (p < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results suggest a viable pathway for developing ML support tools to provide feedback on DDP compliance at an early design stage. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global increase in the elderly population, which is expected to reach 2.1 billion by 2050, has highlighted the need for reliable monitoring systems to assist elderly individuals, especially those with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
29/100
Researchers are focusing on modifiable risk factors for dementia, including sleep disturbances such as insomnia and sleep-disordered breathing (SDB), which are known to increase the risk of dementia, including Alzheimer’s disease (AD) and vascular dementia (VD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild Cognitive Impairment (MCI) is a neuropsychological clinical condition regarded as a prodromal stage of dementia, characterized by cognitive decline without significant impairment in daily functioning or autonomy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Wprowadzenie Obniżenie poziomu funkcjonowania poznawczego to częsty problem osób w wieku podeszłym, zwłaszcza kobiet, a jednym z czynników ryzyka jest brak aktywności fizycznej. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Precision nutrition is a tailored dietary approach that considers an individual’s genetic and metabolic profile, lifestyle factors, and specific nutritional needs to improve health and potentially modify disease progression. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
29/100
Alzheimer disease (AD) is the most common form of dementia, characterized by progressive cognitive decline, memory impairment, synaptic dysfunction, and neurodegeneration. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
RELEVANCE . With age, people experience a decline in cognitive and physical functions, which increases the risk of falls, loss of independence, and deterioration in quality of life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events